NCT03012165View on ClinicalTrials.gov

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Conjunctivitis, Allergic
Interventions
DRUG

ADX-102 Ophthalmic Drops (0.5%)

ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.

DRUG

ADX-102 Ophthalmic Drops (0.1%)

ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.

DRUG

Vehicle of ADX-102 Ophthalmic Drops

Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.

Trial Locations (5)

19148

Philadelphia Eye Associates, Philadelphia

30260

Eye Care Centers Management, Morrow

38119

Total Eye Care, Memphis

45040

Apex Eye Clinical Research, Mason

64133

Silverstein Eye Centers, Kansas City

Sponsors
All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Aldeyra Therapeutics, Inc.

INDUSTRY

NCT03012165 - A Study of ADX-102 in Subjects With Allergic Conjunctivitis | Biotech Hunter | Biotech Hunter